Catalyst Event
Sino Biopharmaceutical Ltd (1177) · Earnings Release
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/26/2026, 12:00:00 AM
Announced FY2025 results: Revenue rose 10.3% to RMB 31.83B, and adjusted net profit rose 31.4% to RMB 4.54B. A final dividend of HKD 0.05 per share was proposed, which is estimated to have a medium price impact (≥5%) due to strong profit growth.
Korean Translation
2025년 회계연도 실적 발표: 매출 318억 3천만 위안으로 10.3% 증가, 조정 순이익 45억 4천만 위안으로 31.4% 증가. 주당 0.05 홍콩달러의 기말 배당금 제안됨. 강력한 이익 성장으로 인해 5% 이상의 중간 수준 주가 영향이 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM